ClinicalTrials.gg
CompletedNCT00393198Updated Nov 3, 2014

Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia

A Phase 4 interventional study of Levonorgestrel (Mirena, BAY86-5028) and Cytotec in Contraception and Menorrhagia, sponsored by Bayer. Completed at 17 sites in 4 countries. Open to female participants aged 23 Years to 45 Years. Per ClinicalTrials.gov, last updated 2014-11-03.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
204
Allocation
Non-randomized
Ages
23 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Menorrhagia by Bayer — none open to participants now, none under way, none of them phase 3. Menorrhagia · Bayer.

Started
2006
with 1 other
Phase 4
Only one
of the 19
Registered
3rd of 19
by date

Among the 19 studies in Menorrhagia by Bayer, this one is one of 2 that started in 2006, is the only one in phase 4, and was the 3rd registered.

Menorrhagia

206 studies on the registry are indexed under Menorrhagia; 35 are open to participants now.

Browse Menorrhagia studies →

Open to participants now

None of the 19 studies in Menorrhagia by Bayer is open now. The open studies under Menorrhagia, anywhere →

Who these studies take

Of the 23 Menorrhagia studies recruiting now, 4 (17%) set no upper age limit and 19 (83%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 23 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Menorrhagia by Bayer as a file.
02

Study summary

The purpose of this study is to assess the bleeding pattern during the last 3 months of the first MIRENA® and the first year of the second MIRENA® use.

Read the detailed description

This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

03

Conditions studied

  • Contraception
  • Menorrhagia

Browse trials for

Keywords

  • Intrauterine System
  • Contraception
  • Menorrhagia
04

Who can participate

Ages eligible
23 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman currently using MIRENA for or menorrhagia with duration use between 4 years 3 months and 4 years 9 months and willingness to continue with the method.
  • Normal size uterus at insertion, corresponding to sound measure of 6-10 cm.
  • Clinically normal cervical smear result within 12 preceding months or at screening.
  • Clinically normal breast examination findings. For patients >/= 40 years at screening, a clinically normal mammography result within 12 preceding months or at screening is required.

Exclusion criteria

Exclusion Criteria:

  • Menopausal symptoms impairing patient's quality of life or current estrogen therapy for menopausal symptoms.
  • Known or suspected pregnancy.
  • Any distortion of the uterine cavity, including congenital or acquired uterine anomalies and fibroids distorting the uterine cavity.
  • Current or recurrent pelvic inflammatory disease.
  • Abnormal uterine bleeding of unknown origin.
  • Acute cervicitis or vaginitis not responding to treatment.
  • History of, diagnosed or suspected genital or other (excluding treated squamous cell carcinoma of the skin), and untreated cervical dysplasia.
  • Any active acute liver disease or liver tumor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Levonorgestrel (Mirena, BAY86-5028)

  • Placebo comparator
    Arm 2

    Drug: Cytotec

  • Active comparator
    Arm 3

    Drug: Placebo

Interventions

  • Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.

  • DrugCytotec

    Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit

  • DrugPlacebo

    Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.

06

What researchers measure

Primary outcomes

  1. Primary efficacy variable will be bleeding profile

    Time frame: Screening, entry (60-90 days after screening), month 3 and 6, year 1,2,3,4 and 5

Secondary outcomes

  1. Secondary efficacy variables will be insertion assessment, continuation rate, pregnancy rate and menstrual comfort and user satisfaction

    Time frame: Screening, entry (60-90 days after screening), month 3 and 6, year 1,2,3,4 and 5

07

Study locations

17 sites
  • Helsinki, 00100, Finland
  • Hyvinkää, 05800, Finland
  • Jyväskylä, 40100, Finland
  • Kuopio, 70110, Finland
  • Tampere, 33100, Finland
  • Turku, 20100, Finland
  • Brignoles, 83170, France
  • Compiègne, 60204, France
  • Nancy, 54042, France
  • Quetigny, 21800, France
  • Reims, 51100, France
  • Roanne, 42300, France
  • Mallow, Cork, Ireland
  • Drogheda, Ireland
  • Stockholm, 118 83, Sweden
  • Stockholm, 182 88, Sweden
  • Stockholm, S-171 76, Sweden
08

References and documents

Publications

  • Heikinheimo O, Inki P, Kunz M, Parmhed S, Anttila AM, Olsson SE, Hurskainen R, Gemzell-Danielsson K. Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system. Contraception. 2010 Jun;81(6):481-6. doi: 10.1016/j.contraception.2010.01.020. Epub 2010 Mar 1. PubMed 20472114 ↗
  • Gemzell-Danielsson K, Inki P, Boubli L, O'Flynn M, Kunz M, Heikinheimo O. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)--a multicentre prospective study. Hum Reprod. 2010 Feb;25(2):354-9. doi: 10.1093/humrep/dep426. Epub 2009 Dec 1. PubMed 19955104 ↗
  • Heikinheimo O, Inki P, Kunz M, Gemzell-Danielsson K. Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. Hum Reprod. 2010 Jun;25(6):1423-7. doi: 10.1093/humrep/deq079. Epub 2010 Apr 8. PubMed 20378611 ↗
  • Heikinheimo O, Inki P, Schmelter T, Gemzell-Danielsson K. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod. 2014 Jun;29(6):1182-8. doi: 10.1093/humrep/deu063. Epub 2014 Mar 28. PubMed 24682613 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2006, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2006
First posted
Oct 27, 2006
Start
Oct 2006
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Last update
Nov 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00393198
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Oct 27, 2006
Start date
Oct 2006
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Nov 3, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion